For a patient prescribed insulin degludec (Tresiba FlexTouch) 100 U/mL pen to inject 25 units subcutaneously in the morning and 25 units in the evening for a 90‑day supply with no refills, how many pens are needed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tresiba FlexTouch 100 U/mL Pen Calculation for 90-Day Supply

You need 5 pens for a 90-day supply.

Calculation Breakdown

Daily insulin requirement:

  • Morning dose: 25 units
  • Evening dose: 25 units
  • Total daily dose: 50 units 1

Total insulin needed for 90 days:

  • 50 units/day × 90 days = 4,500 units total 1

Tresiba FlexTouch 100 U/mL pen specifications:

  • Each pen contains 300 units (3 mL × 100 units/mL) 1
  • The U-100 FlexTouch pen delivers doses in 1-unit increments and can deliver up to 80 units in a single injection 1

Number of pens required:

  • 4,500 units ÷ 300 units per pen = 15 pens

Wait—this calculation appears incorrect based on the prescription showing "twice a day" dosing, which is not the FDA-approved dosing schedule for Tresiba.

Critical Prescribing Error Alert

Tresiba is FDA-approved for once-daily dosing only 1. The prescription as written ("twice a day") does not align with the approved administration schedule, which states: "In adults, inject TRESIBA subcutaneously once-daily at any time of day" and "In pediatric patients inject TRESIBA subcutaneously once-daily at the same time every day" 1.

If the prescription is corrected to once-daily dosing (50 units once daily):

  • 50 units/day × 90 days = 4,500 units
  • 4,500 ÷ 300 units per pen = 15 pens

If the prescription remains as written (25 units twice daily, though off-label):

  • Same calculation: 15 pens

Important Dispensing Considerations

  • Do not perform dose conversion when using Tresiba U-100 FlexTouch pens—the dose window shows the actual number of insulin units to be delivered 1
  • Each pen is a single-patient-use device 1
  • Pens in use should be discarded after 56 days, even if insulin remains 1
  • For this 90-day supply, the patient will need to discard partially used pens at the 56-day mark 1

The prescriber should be contacted to clarify the twice-daily dosing, as this deviates from FDA-approved labeling for Tresiba 1.

Related Questions

What are the clinical implications of a chronically low hemoglobin A1c (3.9%) in a non‑diabetic patient who is not taking insulin or oral hypoglycemic agents?
How should I transition a patient from Tresiba (insulin degludec) to Toujeo (insulin glargine U‑300), including initial dose and titration guidance?
What is the appropriate discharge regimen for a patient receiving a high daily dose of intravenous insulin, transitioning to pre‑meal rapid‑acting insulin boluses, basal insulin glargine, and oral hypoglycemic agents?
What is the typical nighttime glucose profile from bedtime to early morning for an adult with type 2 diabetes mellitus and an HbA1c of 8% who is taking metformin 1000 mg twice daily and bedtime basal insulin glargine 20 units?
What is the equivalent dose of insulin glargine (Lantus) for 23 units of insulin degludec (Tresiba)?
I have progressive forearm pain during fine motor tasks like mouse use, typing, and handwriting; what could be causing this and how should I treat it?
How quickly can the nightly dose of risperidone be increased from 5 mg to 6 mg?
How should I assess and manage an elevated absolute neutrophil count?
What are the recommended treatments for constipation in a 14‑month‑old healthy male who recently switched from breast milk to cow’s milk and now has hard, painful stools?
What is the appropriate evaluation and management for a patient with a low absolute neutrophil count?
Can neurofeedback be used as an adjunct or alternative to repetitive transcranial magnetic stimulation for an adult with obsessive‑compulsive disorder who has already tried selective serotonin reuptake inhibitors or clomipramine and behavioral therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.